Traumatic Brain Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Traumatic brain injury happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head or body. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping, and memory or concentration problems. Risk factor includes age. Certain types of traumatic brain injury increase the risk of developing Alzheimer’s disease and coordination problems.
The traumatic brain injury drugs in development market research report provides an overview of the traumatic brain injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for traumatic brain injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for traumatic brain injury and features dormant and discontinued projects.
What are the targets of the traumatic brain injury pipeline drugs market?
Some of the targets of the traumatic brain injury pipeline drugs market are Cannabinoid Receptor 1, Amyloid Beta A4 Protein, Cannabinoid Receptor 2, Glutamate Ionotropic Receptor NMDA Type Subunit, 5-Hydroxytryptamine Receptor 1A, 5-Hydroxytryptamine Receptor 2A, Microtubule Associated Protein Tau, Neuronal Acetylcholine Receptor Subunit Alpha 7, Apoptosis Associated Speck Like Protein Containing A CARD, and BDNF/NT 3 Growth Factors Receptor.
Traumatic brain injury pipeline drugs market, by targets
For more target insights, download a free report sample
What are the mechanisms of action of the traumatic brain injury pipeline drugs market?
Some of the mechanisms of action of the traumatic brain injury pipeline drugs market are Cannabinoid Receptor 1 Agonist, Amyloid Beta A4 Protein Inhibitor, Cannabinoid Receptor 2 Agonist, 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, Microtubule Associated Protein Tau Inhibitor, Neuronal Acetylcholine Receptor Subunit Alpha 7 Agonist, Apoptosis Associated Speck Like Protein Containing A CARD Inhibitor, and BDNF/NT 3 Growth Factors Receptor Agonist.
Traumatic brain injury pipeline drugs market, by mechanisms of action
For more mechanisms of action insights, download a free report sample
What are the routes of administration in the traumatic brain injury pipeline drugs market?
The routes of administration in the traumatic brain injury pipeline drugs market are intravenous, oral, subcutaneous, nasal, parenteral, intravenous bolus, topical, intracerebral, intrathecal, and sublingual.
Traumatic brain injury pipeline drugs market, by routes of administration
For more routes of administration insights, download a free report sample
What are the molecule types in the traumatic brain injury pipeline drugs market?
The molecule types in the traumatic brain injury pipeline drugs market are small molecule, cell therapy, synthetic peptide, monoclonal antibody, protein, peptide, recombinant protein, biologic, fusion protein, and gene therapy.
Traumatic brain injury pipeline drugs market, by molecule types
For more molecule type insights, download a free report sample
Which are the key companies in the traumatic brain injury pipeline drugs market?
Some of the key companies in the traumatic brain injury pipeline drugs market are Neuronasal LLC, Nyrada Inc, Astrocyte Pharmaceuticals Inc, Athersys Inc, Biogen Inc, Cellvation Inc, Expesicor Inc, Hillhurst Biopharmaceuticals Inc, ImmunoChem Therapeutics LLC, and Mercaptor Discoveries Inc.
Traumatic brain injury pipeline drugs market, by key companies
To know more about key companies, download a free report sample
Market report scope
| Targets | Cannabinoid Receptor 1, Amyloid Beta A4 Protein, Cannabinoid Receptor 2, Glutamate Ionotropic Receptor NMDA Type Subunit, 5-Hydroxytryptamine Receptor 1A, 5-Hydroxytryptamine Receptor 2A, Microtubule Associated Protein Tau, Neuronal Acetylcholine Receptor Subunit Alpha 7, Apoptosis Associated Speck Like Protein Containing A CARD, and BDNF/NT 3 Growth Factors Receptor |
| Mechanisms of Action | Cannabinoid Receptor 1 Agonist, Amyloid Beta A4 Protein Inhibitor, Cannabinoid Receptor 2 Agonist, 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, Microtubule Associated Protein Tau Inhibitor, Neuronal Acetylcholine Receptor Subunit Alpha 7 Agonist, Apoptosis Associated Speck Like Protein Containing A CARD Inhibitor, and BDNF/NT 3 Growth Factors Receptor Agonist |
| Routes of Administration | Intravenous, Oral, Subcutaneous, Nasal, Parenteral, Intravenous Bolus, Topical, Intracerebral, Intrathecal, and Sublingual |
| Molecule Types | Small Molecule, Cell Therapy, Synthetic Peptide, Monoclonal Antibody, Protein, Peptide, Recombinant Protein, Biologic, Fusion Protein, and Gene Therapy |
| Key Companies | Neuronasal LLC, Nyrada Inc, Astrocyte Pharmaceuticals Inc, Athersys Inc, Biogen Inc, Cellvation Inc, Expesicor Inc, Hillhurst Biopharmaceuticals Inc, ImmunoChem Therapeutics LLC, and Mercaptor Discoveries Inc |
This report provides:
- A snapshot of the global therapeutic landscape of Traumatic brain injury (Central Nervous System).
- Reviews of pipeline therapeutics for Traumatic brain injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Key companies involved in Traumatic brain injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
- Evaluation of Traumatic brain injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Traumatic brain injury (Central Nervous System).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Traumatic brain injury (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Traumatic brain injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
AegisCN LLC
AivoCode LLP
AlphaCognition Inc
ALSP Inc
AlzeCure Pharma AB
American CryoStem Corp
Amgen Inc
Anagin Inc
Angion Biomedica Corp
Anida Pharma Inc
Annovis Bio Inc
AntiRadical Therapeutics LLC
Aptinyx Inc
Astrocyte Pharmaceuticals Inc
Astrogen Ltd
Athersys Inc
Avanir Pharmaceuticals Inc
B Cell Solutions Inc
Bessor Pharma LLC
Beyond Barriers Therapeutics Inc
Biogen Inc
BioIncept LLC
Bioquark Inc
Biosplice Therapeutics Inc
Brain-Gen LLC
Braxia Scientific Corp
CalciMedica Inc
Calico Life Sciences LLC
CavoGene LifeSciences
CellCure
Cellvation Inc
CereSpir Inc
Chimerix Inc
Chrysalis BioTherapeutics Inc
Claritas Pharmaceuticals Inc
Cognosci Inc
Complement Pharma BV
Covis Pharmaceuticals Inc
Deha Pharmaceutical LLC
Eagle Pharmaceuticals Inc
Eisai Co Ltd
Emerald Organic Products Inc
Epigen Biosciences Inc
Expesicor Inc
Fortuna Fix Inc
GABA Therapeutics Inc
GNT Pharma Co Ltd
Gryphon Therapeutics Inc
Hemarina SA
Hibernaid Inc
Hillhurst Biopharmaceuticals Inc
Hope Biosciences LLC
Hopstem Biotechnology LLC
Hoverink Biotechnologies Inc
ImmunoChem Therapeutics LLC
Inflammatory Response Research Inc
International Stem Cell Corp
Ischemix Inc
JT Pharmaceuticals Inc
Jupiter Neurosciences Inc
Levolta Pharmaceuticals Inc
M et P Pharma AG
Mapreg SAS
Mercaptor Discoveries Inc
NervGen Pharma Corp
NeuExcell Therapeutics Inc
NeurAegis Inc
Neuren Pharmaceuticals Ltd
NeurExo Sciences LLC
Neurodon LLC
Neuronasal LLC
NeuroNascent Inc
Neuropathix Inc
Neuroplast BV
NeuroTheranostics Inc
NeuroTrauma Sciences LLC
New World Laboratories Inc
NoNO Inc
Noveome Biotherapeutics Inc
NuvOx Pharma LLC
Nyrada Inc
Odyssey Health Inc
OncoSynergy Inc
Orpheris Inc
Oxeia Biopharmaceuticals Inc
Palisade Bio, Inc
Peptron Inc
Personalized Stem Cells Inc
PharmaTher Holdings Ltd
PharmatrophiX Inc
Pinteon Therapeutics Inc
Praetego Inc
ProNeurogen Inc
ProThera Biologics Inc
Protheragen Inc
PurMinds NeuroPharma Inc
Qrons Inc
RegeneRx Biopharmaceuticals Inc
Resolys Bio Inc
Revalesio Corp
Revive Therapeutics Ltd
RHNanopharmacuticals LLC
Rubicon Biotechnology Inc
Samus Therapeutics Inc
SanBio Co Ltd
SciSparc Ltd
Shinkei Therapeutics LLC
Silver Creek Pharmaceuticals Inc
SL Bigen Co Ltd
Spinogenix Inc
STATegics Inc
Stemedica Cell Technologies Inc
Swedish Orphan Biovitrum AB
Synaptogenix Inc
Takeda Pharmaceutical Co Ltd
Tetra Therapeutics
Thera Neuropharma Inc
Therapeutic Solutions International Inc
Theratome Bio Inc
TikoMed AB
Trigemina Inc
vasopharm GmbH
Ventus Therapeutics Inc
VG Life Sciences Inc
Virogenomics BioDevelopment Inc
Vitro Diagnostics Inc
Vivazome Therapeutics Pty Ltd
Wesana Health
Xonovo Inc
ZyVersa Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the traumatic brain injury pipeline drugs market?
Some of the targets of the traumatic brain injury pipeline drugs market are Cannabinoid Receptor 1, Amyloid Beta A4 Protein, Cannabinoid Receptor 2, Glutamate Ionotropic Receptor NMDA Type Subunit, 5-Hydroxytryptamine Receptor 1A, 5-Hydroxytryptamine Receptor 2A, Microtubule Associated Protein Tau, Neuronal Acetylcholine Receptor Subunit Alpha 7, Apoptosis Associated Speck Like Protein Containing A CARD, and BDNF/NT 3 Growth Factors Receptor.
-
What are the mechanisms of action of the traumatic brain injury pipeline drugs market?
Some of the mechanisms of action of the traumatic brain injury pipeline drugs market are Cannabinoid Receptor 1 Agonist, Amyloid Beta A4 Protein Inhibitor, Cannabinoid Receptor 2 Agonist, 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, Microtubule Associated Protein Tau Inhibitor, Neuronal Acetylcholine Receptor Subunit Alpha 7 Agonist, Apoptosis Associated Speck Like Protein Containing A CARD Inhibitor, and BDNF/NT 3 Growth Factors Receptor Agonist.
-
What are the routes of administration in the traumatic brain injury pipeline drugs market?
The routes of administration in the traumatic brain injury pipeline drugs market are intravenous, oral, subcutaneous, nasal, parenteral, intravenous bolus, topical, intracerebral, intrathecal, and sublingual.
-
What are the molecule types in the traumatic brain injury pipeline drugs market?
The molecule types in the traumatic brain injury pipeline drugs market are small molecule, cell therapy, synthetic peptide, monoclonal antibody, protein, peptide, recombinant protein, biologic, fusion protein, and gene therapy.
-
Which are the key companies in the traumatic brain injury pipeline drugs market?
Some of the key companies in the traumatic brain injury pipeline drugs market are Neuronasal LLC, Nyrada Inc, Astrocyte Pharmaceuticals Inc, Athersys Inc, Biogen Inc, Cellvation Inc, Expesicor Inc, Hillhurst Biopharmaceuticals Inc, ImmunoChem Therapeutics LLC, and Mercaptor Discoveries Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Central Nervous System reports